Marinus Pharmaceuticals (NASDAQ:MRNS) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a sell rating to a hold rating in a report published on Wednesday morning.

A number of other equities research analysts also recently commented on MRNS. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a buy rating to a neutral rating in a research report on Wednesday, August 14th. Truist Financial reaffirmed a buy rating and issued a $10.00 price objective on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. HC Wainwright reissued a buy rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a research report on Wednesday, August 14th. Finally, Cantor Fitzgerald restated an overweight rating and set a $13.00 price target on shares of Marinus Pharmaceuticals in a research note on Monday, September 16th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Hold and an average price target of $9.20.

Marinus Pharmaceuticals Trading Up 3.7 %

Marinus Pharmaceuticals stock opened at $1.66 on Wednesday. Marinus Pharmaceuticals has a one year low of $1.05 and a one year high of $11.26. The business’s fifty day moving average is $1.38 and its 200 day moving average is $2.82. The stock has a market capitalization of $91.19 million, a PE ratio of -0.63 and a beta of 1.13. The company has a debt-to-equity ratio of 5.68, a current ratio of 2.28 and a quick ratio of 2.15.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The company had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same period in the previous year, the business earned ($0.61) EPS. On average, sell-side analysts predict that Marinus Pharmaceuticals will post -1.88 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in MRNS. Trexquant Investment LP purchased a new stake in Marinus Pharmaceuticals in the 4th quarter worth approximately $553,000. Franklin Resources Inc. boosted its position in shares of Marinus Pharmaceuticals by 1.3% in the fourth quarter. Franklin Resources Inc. now owns 3,833,955 shares of the biopharmaceutical company’s stock worth $41,675,000 after purchasing an additional 49,589 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Marinus Pharmaceuticals in the fourth quarter worth $1,146,000. Superstring Capital Management LP bought a new stake in shares of Marinus Pharmaceuticals during the 4th quarter valued at $5,027,000. Finally, Wellington Management Group LLP lifted its stake in shares of Marinus Pharmaceuticals by 54.8% during the 4th quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock valued at $2,623,000 after buying an additional 85,455 shares in the last quarter. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.